These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 7368384)

  • 1. [Significance of N-acetyltransferase phenotype in development of bladder neoplasms].
    Wolf H; Lower GM; Bryan GT
    Ugeskr Laeger; 1980 Feb; 142(6):382-5. PubMed ID: 7368384
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.
    Wolf H; Lower GM; Bryan GT
    Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism and cancer susceptibility: evidence concerning acetyltransferases and cancer of the urinary bladder.
    Hein DW
    Bioessays; 1988 Dec; 9(6):200-4. PubMed ID: 3072000
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic regulation of N-acetyltransferase in target organs of arylamine tumors: homologous expression in human and hamster bladder and colon.
    Hein DW
    Proc West Pharmacol Soc; 1991; 34():55-60. PubMed ID: 1788341
    [No Abstract]   [Full Text] [Related]  

  • 5. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer.
    Hanke J; Krajewska B
    Pol J Occup Med; 1988; 1(4):306-11. PubMed ID: 2979565
    [No Abstract]   [Full Text] [Related]  

  • 6. N-Acetyltransferase phenotype of patients with bladder cancer.
    Karakaya AE; Cok I; Sardas S; Gögüs O; Sardas OS
    Hum Toxicol; 1986 Sep; 5(5):333-5. PubMed ID: 3770769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer.
    Weber WW; Hein DW; Litwin A; Lower GM
    Fed Proc; 1983 Nov; 42(14):3086-97. PubMed ID: 6628700
    [No Abstract]   [Full Text] [Related]  

  • 9. Urinary bladder cancer in a girl with a slow-acetylator genotype and treated with sulphasalazine.
    Espin Jaime MT; Moran Penco JM; Garcia Agundez JA; Caballero Loscos MJ; Sanjuan Rodriguez S; Botello Martinez F; Gomez de Tbjada R; Laguna Alvarez E; Benitez Rodriguez I
    Br J Urol; 1997 Jul; 80(1):151-2. PubMed ID: 9240200
    [No Abstract]   [Full Text] [Related]  

  • 10. Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population.
    Hanssen HP; Agarwal DP; Goedde HW; Bucher H; Huland H; Brachmann W; Ovenbeck R
    Eur Urol; 1985; 11(4):263-6. PubMed ID: 4043164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetyltransferase phenotypes of bladder cancer patients in a low-risk population.
    Mommsen S; Sell A; Barfod N
    Lancet; 1982 Nov; 2(8309):1228. PubMed ID: 6128543
    [No Abstract]   [Full Text] [Related]  

  • 12. N-acetyltransferase activity--a susceptibility factor in human bladder carcinogenesis.
    Dewan A; Chattopadhyay P; Kulkarni PK
    Indian J Cancer; 1995 Mar; 32(1):15-9. PubMed ID: 7558106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction.
    Marcus PM; Hayes RB; Vineis P; Garcia-Closas M; Caporaso NE; Autrup H; Branch RA; Brockmöller J; Ishizaki T; Karakaya AE; Ladero JM; Mommsen S; Okkels H; Romkes M; Roots I; Rothman N
    Cancer Epidemiol Biomarkers Prev; 2000 May; 9(5):461-7. PubMed ID: 10815690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [N-acetylation polymorphism versus differentiation of organic susceptibility to carcinogenic effect of homo- and heterocyclic aromatic amines].
    Lutz W; Barański B; Krajewska B
    Med Pr; 1994; 45(4):343-9. PubMed ID: 7968503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and its clinical implications: N-acetylation polymorphism.
    Horai Y; Ishizaki T
    Ration Drug Ther; 1987 Oct; 21(10):1-7. PubMed ID: 3326026
    [No Abstract]   [Full Text] [Related]  

  • 17. [Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany].
    Golka K; Seidel T; Dietrich H; Roth G; Rötzel C; Thier R; Geller F; Reckwitz T; Schulze H
    Aktuelle Urol; 2005 Sep; 36(5):417-22. PubMed ID: 16163604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic association with bladder cancer.
    Wolf H
    Br Med J; 1979 Nov; 2(6201):1366. PubMed ID: 519454
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.
    Hein DW; Doll MA; Gray K; Rustan TD; Ferguson RJ
    Cancer Res; 1993 Feb; 53(3):509-14. PubMed ID: 8425184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study.
    Filiadis IF; Georgiou I; Alamanos Y; Kranas V; Giannakopoulos X; Lolis D
    J Urol; 1999 May; 161(5):1672-5. PubMed ID: 10210437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.